| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharmaceutical company/National Institutes of Health [NIH]) | Year complete | Primary publication | Full study treatment protocol/patient disposition |
|---|---|---|---|---|---|
|
SCORE2 Year 5 (Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion) |
330 | The Emmes Company (NCT01969708) | 2021 | Scott IU, et al. Am J Ophthalmol. 2022;240:330-341. https://www.ajo.com/article/S0002-9394(22)00144-1/fulltext |
|